The BEAM-101 edit is designed to inhibit the transcriptional repressor BCL11A from binding to the promoter without disrupting BCL11A expression, leading to increased production of non-sickling and ...

Updated data from 17 patients treated with BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF) and reductions in sickle hemoglobin (HbS), rapid neutrophil and platelet ...

Some people with sickle cell disease have milder symptoms due to fetal hemoglobin persistence.

The switch from fetal γ-globin to adult β-globin is controlled by BCL11A. Genetic manipulation of BCL11A improves disease outcomes by turning γ-globin expression back on to compensate for ...

Treatment with BEAM-101 demonstrated robust and durable increases in fetal hemoglobin (HbF) and reductions in sickle hemoglobin (HbS), rapid neutrophil and platelet engraftment, and normalized or ...

About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.

FLT1 is among 14 new genetic markers of fetal hemoglobin the scientists identified from GWAS data gathered and used with permission from 3,751 people with sickle cell disease.

--Beam Therapeutics Inc., a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/ 2 clinical ...

The latter is an investigational therapy that produces base edits meant to alleviate the effects of SCD by mimicking genetic variants seen in people with hereditary persistence of fetal hemoglobin.